Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (referred to in metadata as Mbody AI Ltd.) covers the period ending August 12, 2016. The registrant is a foreign private issuer based in Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report details the closing of a registered direct offering of equity securities.
Key Financial Metrics and Transaction Details
The filing discloses a capital raise transaction rather than standard operating financial metrics such as revenue or profit. The specific terms of the offering are as follows:
- Ordinary Shares Sold: 643,614 shares at $1.90 per share.
- Pre-Funded Warrants Sold: 2,514,281 warrants at $1.85 per warrant.
- Warrant Exercise Price: $0.05 per share.
- Warrant Expiration: August 11, 2023.
- Placement Agent: Chardan Capital Markets, LLC.
The filing text does not provide a clear value for total gross proceeds, revenue, net income, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes
The primary material change reported is the expansion of the company's capital structure through the issuance of new ordinary shares and pre-funded warrants on August 11, 2016. This transaction increases the number of outstanding shares and warrants exercisable for shares.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors related to operations. The document focuses solely on the mechanics of the securities offering and incorporates by reference the Securities Purchase Agreement and Placement Agency Agreement as exhibits.
Investor Verification Checklist
- Verify the total gross proceeds generated from the sale of 643,614 shares and 2,514,281 pre-funded warrants.
- Confirm the updated total number of outstanding ordinary shares and warrants following this offering.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or use-of-proceeds restrictions.
- Check subsequent filings for the actual cash balance impact and any dilution effects on existing shareholders.